Abstract:The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein (MAP) kinase family. The jnk1 and jnk2 genes are expressed ubiquitously, whereas jnk3 has a limited pattern of expression and is largely restricted to brain, heart, and testis. The JNKs signal transduction pathway was shown to play an important role in coordinating various cellular responses including apoptosis, proliferation, and neoplastic transformation. Indiscriminately suppressing the activity of all three c-Jun N-terminal kinase isoforms, JNK1, JNK2, and JNK3, is probably not an appropriate strategy because each JNK appears to have a distinct function in cancer, asthma, diabetes, and Parkinson9s disease. However, until now, isoform selective inhibitors for JNK1 over JNK2 or JNK3 activities have not been developed. Therefore, using structure-based design, we developed (in-house) a selective isoform inhibitor that showed a selective inhibitory effect against JNK1, but not JNK2 or JNK3. We found that 7-(6-N-Phenylaminohexyl)amino-2H-anthra[1,9-cd]pyrazol-6-one (AV-7) suppressed JNK1 activity, with no effect on either JNK2 or JNK3, in vitro. In cell culture systems, we also found that AV-7 inhibited JNK1 activity dose-dependently. In contrast to SP600125, a non-selective JNKs inhibitor, that binds to the ATP active site, AV-7 was designed to target the protein-protein interaction between JNK1 and its binding partner(s) rather than the ATP binding site. At 10 μM, AV-7 specifically inhibited JNK1 by about 50%. The phosphorylation of c-Jun by JNKs induces c-Jun transactivation and transcriptional activity through the formation of a protein complex with c-Fos or ATF1 (i.e., AP-1 complex). c-Jun/AP-1 enhances transcription by binding to the promoter region of many genes. We found that AV-7 inhibits UVB-induced c-Jun phosphorylation and sub-G1 accumulation in JNK2 −/− MEFs, which express only JNK1, but had no effect on c-Jun in JNK1 −/− MEFs, which only express JNK2. These results demonstrate that AV-7 is an isoform selective JNK1 inhibitor. In humans, JNKs play a key role in obesity-induced type 2 diabetes mellitus and the absence of JNK1 results in decreased adiposity, significantly improved insulin sensitivity and an enhanced insulin receptor signaling capacity in mouse obesity models. Therefore, we suggest that because of JNK19s critical role in diabetes, AV-7 might have therapeutic potential against this devastating disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3676.

Molecular Cloning and Characterization of Novel Human JNK2 (MAPK9) Transcript Variants That Show Different Stimulation Activities on AP-1

Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38.

Selective interaction of JNK protein kinase isoforms with transcription factors.

Live-cell Imaging and Profiling of C-Jun N-terminal Kinases Using Covalent Inhibitor-Derived Probes.

Differences in the Expression of Neurokinin Receptor in Neural and Bone Marrow Mesenchymal Cells: Implications for Neuronal Expansion from Bone Marrow Cells

Cloning of Human Preprotachykinin-I Promoter and the Role of Cyclic Adenosine 5 '-Monophosphate Response Elements in Its Expression by Il-1 and Stem Cell Factor

Abstract 3676: A selective small molecule inhibitor of c-Jun N-terminal kinase 1

Cloning And Functional Characterization Of C-Jun Nh2-Terminal Kinase From The Mediterranean Species Of The Whitefly Bemisia Tabaci Complex

C-Jun N-terminal Kinase 2 Suppresses Pancreatic Cancer Growth and Invasion and is Opposed by C-Jun N-terminal Kinase 1.

A Novel Transcript Isoform of STING That Sequesters Cgamp and Dominantly Inhibits Innate Nucleic Acid Sensing

Differences in c-Jun N-terminal kinase recognition and phosphorylation of closely related stathmin-family members

Arrestin-3-Dependent Activation of c-Jun N-Terminal Kinases (JNKs)

Activation of JNK/SAPK Pathway in Vero Cells Induced by N-methyl-N'-nitro-N-nitrosoguanidine

Cloning, Characterization and Expression of CDK5RAP1_v3 and CDK5RAP1_v4, Two Novel Splice Variants of Human CDK5RAP1.

Cloning and Characterization of a Novel Human TGF-β Activated Kinase-Like Gene

Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways

Molecular Identification and Functional Characterization of a Drosophila Dual-Specificity Phosphatase DMKP-4 Which is Involved in PGN-induced Activation of the JNK Pathway.

JNK is Required for Maintaining the Tumor-Initiating Cell-Like Properties of Acquired Chemoresistant Human Cancer Cells.

A conserved motif in JNK/p38-specific MAPK phosphatases as a determinant for JNK1 recognition and inactivation

A Novel Transcript Encoding an N-terminally Truncated AML1/PEBP2 Alphab Protein Interferes with Transactivation and Blocks Granulocytic Differentiation of 32dcl3 Myeloid Cells

TAB1β (Transforming Growth Factor-β-activated Protein Kinase 1-binding Protein 1β), a Novel Splicing Variant of TAB1 That Interacts with p38α but Not TAK1